BioAgilytix Implements BD FACSLyric™ Platform in Its European Laboratory

High-Performance Clinical Cell Analyzer Enhances BioAgilytix’s Flow Cytometry Capabilities and Extends Capacity for Immune Response Monitoring and Cell Line Characterization

MAY 18, 2017—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has added the BD FACSLyric™ platform to the arsenal of state-of-the-art flow cytometers available in its European headquarters, IPM Biotech. Considered the most advanced FACS analysis platform, the FACSLyric offers a high level of standardization to help maximize compatibility, repeatability, and quality for increasingly complex immunoassay studies. In addition, the 10-color instrument is FDA 21 CFR Part 11 compliant and can be used for both GLP/GCP compliant projects as well as research projects utilizing two distinct operating modes. BioAgilytix is a long-standing leader in the utilization of flow cytometry platforms for diverse large molecule studies, and the FACSLyric represents the next evolution in flow cytometry technology for the organization to leverage as it continues to deepen its expertise. FACSLyric also gives BioAgilytix added flexibility to support both routine clinical analysis and clinical research for projects involving immune monitoring of patients, analysis of immune response within cell therapy, and cell line characterization.

“The consistency and the regulatory compliance of FACSLyric’s output is what really drew us to the platform. It is currently unmatched by other flow cytometers in its ability to generate reliable, repeatable results across tests and instruments – even for the most complex assays we deal with day to day. This instrument gives us a strong boost in supporting cell therapeutic programs,” said Dr. Arno Kromminga, Chief Scientific Officer, BioAgilytix Europe/IPM Biotech. “This new platform, paired with our scientific team’s depth of expertise using FACS analysis for immunogenicity, biomarkers, and cell-based assays, will help ensure we continue to deliver superior results that support the advancement of our pharmaceutical and biotechnology customers’ biotherapeutic innovations.”

BioAgilytix is continuously investing in strategic technologies like FACSLyric to advance its laboratories in both Europe and USA, and to better serve global customers’ increasingly complex bioanalytical demands with platforms that uphold exceptional accuracy and consistency.

###

About BioAgilytix

BioAgilytix is a leading global bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, spirit-of-GLP, GLP, and GCP, as well as product release testing under GMP./p>

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to 23 of the top 25 global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.

Media Contact:
Carla Nieser
Vovéo Marketing Group
610.240.0400, x 118
c.nieser@voveo.com

Share This